SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors eagerly anticipate earnings, with many hoping for a strong report to push the stock higher. Community discussions revolve around potential S&P 500 inclusion and the impact of future interest rate cuts on the fintech company. Bullish sentiment is high, with some comparing SoFi to other disruptive tech stocks.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending due to a recently announced $1 billion private offering of exchangeable senior notes, leading to concerns about potential dilution despite a strong earnings report. The community is debating whether this is a strategic move to fuel growth in AI/data centers or a sign of financial strain. Discussions also involve the broader context of crypto treasuries and comparisons to similar offerings from other companies.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors anticipate upcoming earnings, with community debates focusing on whether the company can maintain margins and growth amid industry cost pressures. Bullish sentiment revolves around potential catalysts such as ACA subsidies and Optum's performance, while bears are pointing to sector-wide headwinds and the potential for disappointing guidance. Some traders are expressing nervousness about holding large positions through earnings.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community anticipates a potential ETF listing, sparking excitement about institutional investment and increased liquidity. Community members are discussing potential price appreciation and real-world use cases. Some investors express frustration with the token's historical performance, while others remain optimistic about its long-term potential amid regulatory developments.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics ($NTLA) is trending due to a trial pause after a patient experienced liver enzyme elevations, sparking a sharp decline in the stock price. The community is debating the severity of the event, the potential impact on Intellia's pipeline, and whether the sell-off is an overreaction or a buying opportunity.  Some investors are optimistic about a potential rebound, while others express concerns about the safety profile of the gene-editing therapy.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the potential impact of restructuring efforts and upcoming earnings, with community members discussing dividend sustainability and volume concerns. Some traders express optimism based on after-hours activity and potential for a holiday season boost, while others fear a dividend cut and continued struggles with profitability. The stock's valuation and potential takeover scenarios are also circulating as talking points.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA Labs is trending as the community discusses its potential, particularly in comparison to the previous $WORM project, highlighting its AI utility and 'Worminal' launch. Bullish sentiment is fueled by the project's migration, perceived improved liquidity, and the upcoming release of 'Nema Pets' which are seen as next-level Tamagotchis on the Solana blockchain. Chatter suggests a migration from $WORM to $NEMA with community members emphasizing that NEMA has utility and scientists.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending after announcing its entry into the AI accelerator chip market, posing competition for Nvidia and AMD; this news has sparked a surge in the stock. Community members are debating whether Qualcomm's fundamentals justify the rally or if it's just hype, while also analyzing its potential impact on the broader semiconductor landscape and AI infrastructure.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors discuss the company's recent capital raise and its potential impact on funding the launch of its satellites for global 5G coverage; the community is analyzing upcoming earnings and potential military applications, while debating the stock's valuation and future prospects amid competition in the satellite connectivity sector.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending due to a surge in price action, sparking excitement and FOMO among investors, with many drawing comparisons to past crypto successes. Community members are actively discussing potential price targets and adding to their positions, while some caution against a potential pump and dump scenario. The broader context includes Virtual Protocol's focus on AI agents and its presence on the Base network, contributing to its appeal within the crypto ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?

Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at supporting the latter’s plans for global development of its investigational cancer drug Daraxonrasib.As per the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-enters-2-billion-flexible-funding-agreement">arrangement</a>, Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.Synthetic royalty financing is a type of funding where a company sells a portion of its future revenue stream in exchange for upfront capital, without relinquishing ownership of the underlying asset.Funds worth $1.25 billion will be awarded in five tranches upon Revolution Medicines hitting certain product development milestones. The first two $250 million tranches, totaling $500 million, are payable prior to the FDA’s approval of Daraxonrasib, and royalty obligations begin only after that.The funds, Royalty Pharma said, will support Revolution Medicines’ plans for global development and commercialization of Daraxonrasib and its pipeline programs for patients with RAS-addicted cancers.Daraxonrasib is an experimental drug in late-stage development for RAS mutant pancreatic cancer and non-small cell lung cancer (NSCLC). RAS is one of the most commonly mutated genes in human cancer, and the drug works by targeting RAS proteins.In the U.S., approximately 56,000 patients are diagnosed with RAS-driven pancreatic cancer annually, while approximately 60,000 patients are diagnosed with RAS-driven NSCLC annually, Royalty Pharma said.Revolution Medicines expects late-stage trial results for Daraxonrasib in pancreatic cancer in 2026.Revolution Medicines CEO Mark A. Goldsmith said that the funding agreement “significantly increases” the financial resources the company can deploy.The company had cash, cash equivalents, and marketable securities of $2.1 billion as of March 31. The company said on Tuesday that it is removing its cash runway end date guidance owing to the new funding agreement.On Stocktwits, retail sentiment around RVMD fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume increased from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_43_59_AM_png_4b2fb6ec49.webp" alt="RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>As for RPRX, retail sentiment stayed unmoved within ‘bearish’ territory over the past 24 hours while message volume improved from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:631/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_45_20_AM_png_2660096f57.webp" alt="RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits" width="631" height="66"><figcaption>RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure> RVMD is trading nearly 2% lower on Tuesday morning.While <a href="https://stocktwits.com/symbol/RVMD">RVMD stock</a> is down by about 10% this year, <a href="https://stocktwits.com/symbol/RPRX">RPRX</a> is up by about 41%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/verizon-ai-powered-overhaul-of-customer-support-draws-retail-praise/chm49CNRR34">Verizon’s AI-Powered Overhaul Of Customer Support Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revolution Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.

Equity

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A